Global warming will lead to “an increase in the amount of pollen,” causing respiratory discomfort or allergies, warned three monitoring networks in their annual report published Tuesday.
In 2018, this observation was confirmed through birch pollen records reaching an abnormal peak of concentrations during April, adds the report.
Allergy Therapeutics (LON:AGY) is an international commercial biotechnology group focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.